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Summary 
Five unrelated children are described with a rare auto- 
immune lymphoproliferative syndrome (ALPS) charac- 
terized by massive nonmalignant lymphadenopathy, 
autoimmune phenomena, and expanded populations 
of TCR-CD3 + CD4-CD8- lymphocytes. These findings, 
suggesting a genetic defect in the ability of T lympho- 
cytes to respond to normal immunoregulatory mecha- 
nisms, prompted an evaluation of lymphocyte apop- 
tosis. Each child had defective Fas-mediated T 
lymphocyte apoptosis associated with a unique, dele- 
terious Fas gene mutation. One mutation appeared to 
cause a simple loss of function; however, four others 
had a dominant negative phenotype when coex- 
pressed with normal Fas. Family studies demonstrated 
the inheritance of the mutant Fas alleles. The occur- 
rence of Fas mutations together with abnormal T cell 
apoptosis in ALPS patients suggests an involvement 
of Fas in this recently recognized disorder of lympho- 
cyte homeostasis and peripheral self-tolerance. 
Introduction 
Apoptosis (or programmed cell death) plays a decisive 
regulatory role not only during T cell ontogeny but also in 
immune responses involving mature peripheral T lympho- 
cytes. It is well established that immature thymocytes 
bearing autoreactive receptors can be efficiently elimi- 
nated if they encounter ligand during thymic development 
(Burner, 1969; Kappler et al., 1987; Hengartner et al., 
1988; Kisielow et al., 1988). More recent studies indicate 
that peripheral, mature T lymphocytes also undergo anti- 
gen-stimulated apoptosis under appropriate conditions 
(Lenardo, 1991; Russell et al., 1991; Critchfield et al., 
1994). Following immunization with superantigens or pep- 
tide antigens, specific T cell clones expand, but then are 
reduced or eliminated upon restimulation, particularly by 
*The first wo authors contributed equally to this work. 
high concentrations of antigen. Programmed cell death 
acts to preserve peripheral T cell homeostasis, regulating 
the tempo and duration of immune responses in vivo 
(Jones et al., 1990; Webb et al., 1990; Rocha and von 
Boehmer, 1991; Kawabe and Ochi, 1991; Kyburz et al., 
1993; Moskophidis et al., 1993; Critchfield et al., 1995; 
McHeyzer-Williams and Davis, 1995). 
Studies of mouse strains with genetic predispositions to 
autoimmune disease suggest that in addition to regulating 
responses to exogenous antigens, apoptosis of mature 
T cells maintains tolerance to self-antigens (Theophilo- 
poulos and Dixon, 1968; Nagata and Golstein, 1995). Mice 
homozygous for the Ipr or gld mutations manifest hyper- 
gammaglobulinemia, utoantibody production, glomeru- 
Ionephritis, arthritis, vasculitis, and accumulation of non- 
malignant TCRaI~+CD4-CD8 - T lymphocytes in their 
secondary lymphoid organs. Understanding the Iprand gld 
defects began with the isolation of monoclonal antibodies 
(MAbs) that induced apoptosis when bound to the cell sur- 
face receptor Fas (also designated CD95, Apo-1, Fas anti- 
gen, and Apt) (Trauth et al., 1989; Yonehara et al., 1989). 
Genetic cloning and mapping studies revealed that Iprwas 
a recessive mutation in Fas, while gld was a mutation in 
the gene for Fas ligand (FasL) (Watanabe-Fukunaga et 
al., 1992; Takahashi et al., 1994"; Lynch et al., 1994). Ho- 
mozygosity for either Ipr or gld causes defective T cell 
receptor (TCR)-induced death of mature T cells (Russell 
et al., 1993; Gillette-Ferguson and Sidman, 1994; Alder- 
son et al., 1995; Dhein et al., 1995). Thus, autoimmunity 
in mice with these gene defects seems to be predomi- 
nantly due to a failure in peripheral, rather than thymic, 
T cell deletion (Singer and Abbas, 1994). 
Fas and FasL are members of two superfamilies of com- 
plementary receptors and ligands that are important in 
immune regulation (Smith et al., 1994; Nagata, 1994; Na- 
gata and Golstein, 1995). Fas belongs to the tumor necro- 
sis factor receptor (TNFR) superfamily, which includes the 
two TNFRs (type I, which is also known as p55, and type 
II, which is also known as p75), the low affinity nerve growth 
factor receptor, CD27, CD30, CD40, OX40, and 4-1BB. 
These membrane-spanning receptors have 20%-25% 
amino acid identity and contain variable numbers of extra- 
cellular cysteine-rich domains (CRDs) (Banner et al., 1993), 
regions approximately 40 amino acids in length with six 
cysteine residues in conserved positions. There are four 
CRDs in the p55 TNFR and three in the Fas protein. The 
crystallographic structure of the p55 TNFR and other bio- 
chemical evidence suggest that the functional receptor 
is a trimeric complex with a threefold axis of symmetry 
perpendicular to the cell membrane. In contrast with their 
extracellular homology, the cytoplasmic regions of TNFRs 
have little amino acid conservation, except for Fas and 
the p55 TN FR. These two receptors share a 70 amino acid 
intracellular "death domain" that transduces signals for 
cell death (Tartaglia et al., 1993; Itoh and Nagata, 1993). 
FasL and other related ligand proteins also form trimers 
of subunits in a conical configuration with threefold sym- 
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metry that complements the receptor complex structure. 
When ligand is bound, it is embraced on three sides by 
the individual receptor subunits, which adopt an extended 
linear conformation with their long axes nearly parallel to 
one another and projecting from the membrane. The 
CRDs maintain receptor subunit conformation by means 
of intracysteine disulfide bonds so that interaction with 
ligand can occur. The trimeric association of receptor and 
ligand subunits appears to be crucial for signal gener- 
ation on the intracellular side of the receptors (Banner et 
al., 1993). 
While inbred mouse strains bearing Ipror g/d mutations 
provide convincing evidence that failure of mature T cell 
deletion may breach peripheral tolerance, such evidence 
has been lacking in humans. However, an association be- 
tween lymphoproliferation a d autoimmune disease was 
noted recently in two children with lymph node enlarge- 
ment, hypergammaglobulinemia, and expansion of an oth- 
erwise minor population of TCR~+CD4-CD8 - T lympho- 
cytes (Sneller et al., 1992). Additional studies have been 
undertaken on the first patient in the report by Sneller et 
al. (1992) and on four additional individuals with the same 
constellation of findings, which we have designated auto- 
immune lymphoproliferative syndrome (ALPS). In this re- 
port we show that the CD4 ÷ and CD8 ÷ single-positive T
lymphocytes from each child affected with ALPS had de- 
fective TCR-induced apoptosis in association with delete- 
rious mutations of the human Fas gene (APT1). The mutant 
Fas alleles, in contrast with Ipr in the murine disease, were 
heterozygous in affected patients, and four demonstrated 
a dominant interfering effect on apoptosis. The association 
of defects in a T lymphocyte apoptosis effector molecule 
with a human syndrome of autoimmunity and lymphoproli- 
feration provides a basis for further dissection of the 
causes of human autoimmune disease. 
Results 
Clinical Features of ALPS 
Five children came to medical attention because of lymph 
node and spleen enlargement as early as 2 months after 
birth (Table 1). Generalized hypercellularity ofthe second- 
ary lymphoid organs, often of massive proportions, was 
exhibited by these children and required removal of en- 
larged spleens in four of them. In all cases, the increased 
populations of cells in the lymph nodes and blood ap- 
peared to be lymphocytic, but no malignant transformation 
or metastasis to nonlymphoid organs has occurred. There 
was no evidence of opportunistic infection (other than 
postsplenectomy sepsis in two children) or any form of 
chronic immune stimulation. In each patient, a normally 
minor population of mature TCR-CD3 ÷ T lym phocytes that 
lacked CD4 and CD8 expression (double negative) was 
expanded 3- to 60-fold. In four of the five children, these 
double-negative T cells, both in the circulation and in biop- 
sied lymph nodes, expressed ~1~ TCRs. In patient 4, how- 
ever, the double-negative T cells in the lymph nodes 
expressed ~z~ TCRs, whereas most circulating double- 
negative T cells expressed 7,5 TCRs. Double-negative T 
cells in these patients responded poorly to TCR engage- 
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Figure 1. T Cells from ALPS Patients Show Defective Apoptosis 
The percent T cell loss induced by MAb anti-CD3s (64.1), prebound 
at 1 p.g/ml to plastic wells, in samples from patients 2, 3, 4, and 5 and 
from normal individuals, controls A, B, and C. Values are the arithmetic 
means with standard deviations from three independent determina- 
tions. 
ment and produced significantly less interleukin-2 (IL-2) 
and interferon-~, than did normal T cells (Sneller et al., 
1992; data not shown). All patients had 5- to 20-fold eleva- 
tions in B lymphocyte and natural killer cell numbers in 
blood and lymphoid organs, but no abnormalities in the 
the bone marrow. 
Each of the children also manifested clinically significant 
autoimmune disease (Table 1). All suffered episodes of 
autoimmune hemolytic anemia, thrombocytopenia, neu- 
tropenia, or some combination of these. Autoantibodies 
against red blood cells and platelets were demonstrated 
in patients 3 and 5. All patients had recurrent urticarial 
rashes consistent with immune vasculitis. Moderate 
growth retardation was evident in three patients, and pa- 
tient 2 required several cycles of dialysis for renal insuffi- 
ciency due to glomerulonephritis. These complications 
could each be attributed to immune hyperreactivity and 
deposition of antigen-antibody complexes. Consistent 
with this explanation, laboratory studies showed all pa- 
tients to have hypergammaglobulinemia. Taken together, 
the clinical picture of children with ALPS was consistent 
with normal lymphocyte generation, but severely impaired 
control of mature lymphocyte homeostasis in the periph- 
ery. Although no patient had a family history of similar 
illnesses, the father of patient 3 and other members of his 
family had Hodgkin's disease. 
Defective Apoptosis via TCR Restimulation 
To examine the basis for dysregulated lymphoproliferation 
and autoimmunity in ALPS, we considered a defect in ma- 
ture T lymphocyte cell death. As a screen for impaired 
apoptosis, peripheral blood lymphocytes (PBLs) from pa- 
tients 2-5 and controls were primed with phytohemaggluti- 
nin, anti-CD3 MAb (OKT3), and IL-2 (Pelfrey et al., 1995). 
Apoptosis was then induced by cross-linking the TCR- 
CD3 complex with anti-CD3s MAb (64.1) immobilized in 
culture wells. This stimulation resulted in the apoptotic 
loss of 40%-55% of control lymphocytes (Figure 1). In 
contrast, significantly reduced destruction, 0%-15% cell 
loss, occurred in lymphocytes from the four ALPS patients 
tested. A failure of programmed cell death was confirmed 
by direct detection of fragmented DNA ends after anti-CD3 
exposure in the control samples, but not in the samples 
of ALPS patients (data not shown). 
The differences in ability to undergo apoptosis were not 
due to differences in composition of the cell populations 
between patient and control cultures. As previously noted 
by Sneller et al. (1992), the abnormal TCRa~+CD4-/CD8 - 
lymphocytes of our patients responded poorly to stimula- 
tion and were rapidly lost during in vitro cultivation. Thus, 
at the time of assay for apoptosis, all cultures contained 
>98% single-positive CD4 + or CD8 ÷ mature T lymphocytes 
(data not shown). In addition, poor proliferation of the sin- 
gle-positive T cells of the patients, which would render 
them resistant o apoptosis (Boehme and Lenardo, 1993), 
was excluded by testing all cultures for proliferation at the 
time of assay. Finally, the lymphocytes from patients 3, 
4, and 5 demonstrated intact apoptotic responses when 
stimulated by topoisomerase inhibitors or other antimetab- 
olites that induce apoptosis in cycling T cells, indicating 
that the T cells of the patients were not innately resistant 
to programmed death (data not shown). We therefore con- 
cluded that patients with ALPS had a significant defect in 
the TCR-induced pathway to apoptosis in their mature T 
lymphocytes. 
Fas Mutations in Affected Patients 
Because Fas-mediated apoptosis has been recently impli- 
cated in T cell homeostasis and maintaining peripheral 
tolerance, we considered Fas as a candidate disease gene 
for ALPS patients. We analyzed the Fas genomic locus 
and Fas mRNA, cloned after reverse transcription-poly- 
merase chain reaction (RT-PCR), from activated lympho- 
cytes of patients and available family members. Sequence 
determination of cDNAs spanning the complete 1.1 kb 
coding region of the 2.5 kb mRNA revealed that each of 
the five ALPS patients expressed one or more abnormal 
Fas mRNAs in addition to normal Fas mRNA. The abnor- 
mal Fas allele of patient 1 had a single base deletion of 
G429. His mutant transcript would thus encode a normal 
Fas protein only up to the middle of the first CRD (CRD1), 
followed by 34 missense amino acids and a premature 
termination (Figure 2A), and therefore cause a loss of 
function. 
Lymphocytes from patients 2 and 4 yielded Fas RT- 
PCR products, visualized with ethidium bromide staining, 
of abnormal as well as normal sizes, suggesting mutations 
involving mRNA splicing. Two abnormally small cDNA 
species from patient 2 proved upon sequence analysis to 
lack, in one case, exon 3 and, in the other, exons 3 and 
4 (see diagram in Figure 2B). Genomic sequence determi- 
nation revealed that the aberrant splicing was due to the 
duplication of a T residue in the 5' splice site of intron 3, 
changing the normal GTAAG to GTTAAG, which is unlikely 
to function as a splice donor site (Krawczak et al., 1992). 
The relative quantity of cDNA produced from mutant allele 
of patient 2 after RT-PCR was comparable to that from 
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Figure 2. Fas Gene Is Mutated in ALPS Pa- 
tients 
(A) Structure of human Fas gene locus (APT1, 
APO-1), illustrating the nature and location of 
mutations with respect to signal peptide se- 
quence, three CRDs, transmembrane (TM) re- 
gion, and intracytoplasmic death domain in- 
volved in signal transduction, cDNA nucleotide 
and amino acid numbers correspond to Itoh et 
al. (1991); exon numbers and boundaries are 
as reported by Behrmann et al. (1994) and are 
available from GenBank (accession umbers 
X81334-X81342). 
(B) Mechanism of the formation of abnormally 
spliced Fas mRNA species in lymphocytes of
patients 2 and 4. 
(C) Examples of sequence determination of 
Fas mutations from ALPS patients in individual 
normal and mutant cDNA clones for patients 
3 and 5, genomic clones from patient 4, and 
directly amplified genomic DNA for each of these 
patients. Nucleotide base order: A, C, G, T. 
her normal allele, suggesting that mRNA production and 
stability were not compromised by the mutation. The small- 
est mRNA (lacking exons 3 and 4) of patient 2 was pre- 
dicted to have a frameshift and consequential premature 
termination after 21 missense codons, whereas the mRNA 
lacking exon 3 encoded an in-frame Fas protein in which 
the first two CRDs (CRD1 and CRD2) were foreshortened 
and fused into one. 
Patient 4 expressed both a normal and a slightly en- 
larged Fas mRNA. The large Fas mRNA was produced 
by the interposition of nucleotides from the distal half of 
intren 6 (Figure 2B). The genomic sequence of the mutant 
allele of patient 4 showed an A to C transversion in the 
3' splice site of intron 6, changing the invariant AG to a 
nonfunctional CG (Figure 2C). An alternate 3' splice motif 
(TAG) that was 72 bp 5'to exon 7 was used as the 3' splice 
site for this allele, thereby causing the inclusion of the 
intron 6 nucleotides in the abnormally processed tran- 
script. This aberrant mRNA thus encoded the first six Fas 
exons, including the transmembrane domain, followed im- 
mediately by an in-frame termination codon. 
Single nucleotide substitutions found in Fas cDNA from 
patients 3 and 5 were confirmed by direct sequencing of 
genomic DNA (Figures 2A and 2C). Patient 3 had an A 
to C transversion at cDNA nucleotide 915 in one allele, 
producing a nonconservative substitution of proline for 
Thr-225. in patient 5, a premature termination was intro- 
duced by a C to T transition at cDNA nucleotide 1011, 
substituting a TAG stop codon for Glu-257. His mutant 
allele was noted to have the A allotype (Fiucci and Ruberti, 
1994), positively distinguishing it from the normal allele, 
which was atlotype B. Mutations in both these patients lay 
in the intracellular death domain of Fas (Itoh and Nagata, 
1993; Tartaglia et al., 1993), as shown in Figure 2A. 
Mothers of all five patients, fathers of three, and the 
healthy brother of patient 1 were studied. Father 3 was 
deceased from Hodgkin's disease. However, a DNA sam- 
ple obtained from his brother (the paternal uncle of patient 
3), who also had been diagnosed with Hodgkin's disease, 
showed heterozygosity for the same mutation as patient 
3 himself. This indicated that father 3 was the source of 
the mutation in patient 3. Moreover, genomic DNAs from 
lymphocytes of mothers 1,2, 4, and 5 each had one normal 
Fas allele and one with the identical Fas mutations found 
in their children affected with ALPS (Figure 3A). Interest- 
ingly, the lymphocytes from mother 4 yielded multiple Fas 
genes, including both A and C allotypes with a normal Fas 
coding sequence, as well as agene of allotype C bearing 
the mutation found in her son. This finding, along with a 
normal 46XX karyotype, suggested that mother 4 was a 
mosaic for this Fas mutation, which would therefore be 
present in only a portion of her bone marrow-derived cells 
and germ cells. Full-length Fas cDNA sequences of at 
least ten RT-PCR clones or clones of different allotypes 
from fathers 1,2, and 4 and from mother 3 were normal. 
Lack  of Fas  Mutat ions  in Normal  Ind iv idua ls  
Unlike polymorphisms in the human Fas gene reported 
by Fiucci and Roberti (1994), which do not alter the amino 
acid sequence of the protein, the mutations found in pa- 
tients with AEPS and their parents would be predicted to 
have detrimental effects on Fas protein function. Nonethe- 
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less, it was important o establish whether such mutations 
occur commonly in the general population. Single strand 
conformation polymorphism analysis of PCR-amplified 
Fas genomic fragments, using primers flanking or within 
the coding regions (Table 2), readily detected altered mo- 
bility patterns produced by each of the ALPS patient muta- 
tions. No instance of any of these alterations was seen in 
either Fas allele from DNA from 20 unrelated individuals 
in the Centre d'Etudes du Polymorphisme Hu main (CEPH) 
genome mapping collection or from 30 additional unre- 
lated normal subjects, comprising a total of 100 indepen- 
dent examples of the Fas locus on chromosome 10q23 
(data not shown). 
Apoptosis via Fas Cross-Linking 
To determine whether the above Fas mutations were asso- 
ciated with specific Fas-mediated defects in apoptosis, 
activated and IL-2-treated lymphocytes from patients 1-4 
and their family members were stimulated with 1 i~g/ml of 
the agonistic anti-Fas MAb CH11 (Itoh et al., 1991). In all 
patients, there was a defect in Fas-mediated T cell death 
compared with family members who did not have a mutant 
Fas gene (Figure 3A) or to ten normal controls (Figure 3B). 
Figure 3. Fas Mutations and Apoptosis Defects Are inherited 
(A) Partial pedigrees from families 1-4. Patients affected with ALPS 
are shown by closed symbols; unaffected individuals, open symbols; 
squares, males; circles, females; slash, deceased. The genotypes indi- 
cate the presence of normal (plus sign) or mutant (mt) alleles, as de- 
scribed in Figure 2. In all cases, complete nucleotide sequence deter- 
mination proved the parental mutant Fas allele as identical to that in 
the affected. Graphs show percent T cell loss after exposure to 1 
i~g/ml anti-Fas MAb CH11 (IgM). Values are averages from duplicate 
determinations for the patients and indicated family members. 
(B) Average percent cell loss for lymphocyte samples from ten different 
healthy individuals. Two independent determinations were made for 
each individual using the concentrations of CH11 shown. Data were 
pooled for each CH11 concentration and, standard deviations of all 
determinations were calculated. Below 0.1 I~g/ml of CH11, decreased 
T cell apoptosis was seen (data not shown). 
Table 2. Primers Used for PCR and Analysis of Fas Sequence 
Primers cDNA Location Sequence 
Primers surrounding coding region 143-164 
1643-1622R 
1243-1221R 
362-385 ex2F 
421-440 ex3F 
549-569 ex4F 
739-761 ex6F 
951-975 ex9F 
1243-1221 ex9R 
989-962 ex9R 
792-767 ex7R 
562-542 ex4R 
350-328 ex2R 
ex3-5' 
ex3-3' 
ex7-5' 
ex7-3 r
ex9-5' 
Primers within coding region 
Intron primers flanking exons 
CTCAGTACGGAGTTGGGGAAGC 
ATTTAGAGGCAAAGTGGCCTGC 
CTAATTGCATATACTCAGAACTG 
CCAATTCTGCCATAAGCCC 
ATGGGGATGAACCAGACTGC 
TGCACCCGGACCCCAGAATACC 
TGCCAATTCCACTAATTGTTTGG 
GGTGTCAATGAAGCCAAAATAGATG 
CTAATTGCATATACTCAGAACTG 
GTCATTCTTGATCTCATCTATTTTGGCT 
TGCATGTTTTCTGTACTTCCTTTCTC 
TGGGTCCGGGTGCAGTTTATT 
CAGGCCTTCCAAGTTCTGAGTCT 
TTGTCTGTCATCCCTCTATACTTCCC 
ATTTGAGCTGATGAACCCTGTTCC 
CATGCATTCTACAAGGCTGAGACC 
TTTTCTTTTCAAGGAAAGCTGATACC 
CTGAAGTACTATAAAAGAGAAAT 
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Figure4. Fas Mutations Cause Defective 
Transmission of Apoptotic Signals 
Left y axis (open or hatched bars) shows per- 
cent of transfected BW5147 murine thymoma 
cells expressing a human Fas molecule. Sur- 
face-expressed human Fas was detected using 
flow cytornetry with MAb UB2 (open bars) or 
anti-rabbit (Fas amino-terminal peptide) serum 
(hatched bar). Right y axis (closed bars) shows 
percent cell loss after exposure to human anti- 
Fas MAb CH11. DNAs used for transfection 
were 10 p.g of expression plasmid pCI with no 
insert or with either normal or mutant Fas al- 
leles as indicated. 
Transfected DNA 
Doses of 0.1-2.5 p.g/ml of CH 11 caused the same degree 
of cell loss in normal controls, an indication that the anti- 
body was present in saturating amounts (Figure 3B). Test- 
ing of >30 stimulated lymphocyte samples from healthy 
individuals unrelated to the ALPS patients showed robust 
apoptosis induction (60%-80% cell loss) by the CH 11 anti- 
body in this assay (examples in Figure 3B), demonstrating 
that defective lymphocyte apoptosis is not common in nor- 
mal individuals. 
Interestingly, mothers 2 and 4, who carried Fas muta- 
tions, but manifested no clinical abnormalities, showed 
impairment in T lymphocyte apoptosis, and cell loss of 
lymphocytes from mother 1 was at the lower end of the 
normal range. Mother 2 (top right in Figure 3A) exhibited 
cell loss comparable to that of her daughter with ALPS and 
significantly less than father 2, who had no Fas mutation. 
Mother 4 showed T cell loss that was intermediate between 
that of her son with ALPS and that of the non mutant father, 
possibly due to her genetic mosaicism. In the family of 
patient 3, the Fas mutation-bearing lymphocytes of nei- 
ther the paternal uncle nor the father were available for 
study. Interestingly, lymphocytes from mother 3, who car- 
ried no Fas mutation, exhibited greater cell loss than the 
affected child, but still less than normal controls, raising 
the question whether mother 3 could have contributed to 
patient 3 an abnormality in a molecule other than Fas in 
the apoptosis pathway. 
Coexpression of Normal and Mutated Fas Alleles 
in ALPS Carrier Parents 
It seemed paradoxical that parents could harbor Fas muta- 
tions and yet fail to manifest clinical features of ALPS. 
Possible explanations included instability of mutant Fas 
mRNA in parental lymphocytes or transcriptional silencing 
that could prevent mutant Fas protein expression in the 
unaffected parents. Because of the abnormal sizes of the 
aberrantly spliced mutant mRNAs in mothers 2 and 4, we 
were able to test whether the mutant alleles produced sta- 
ble mRNA. Semiquantitative RT-PCR followed by aga- 
rose electrophoresis and ethidium bromide staining 
showed substantial quantities of mutant along with nor- 
mal-sized cDNA from lymphocytes of both mothers 2 and 
4 (data not shown). Their ratios of mutant o normal cDNA 
appeared comparable to those observed in ALPS patients 
2 and 4, an indication that both mothers, as well as their 
children, expressed the abnormal Fas alleles. 
Defective Apoptosis Caused by Fas Mutations 
To test directly whether the mutant Fas genes in ALPS 
patients encoded proteins that were functionally defective, 
normal and mutant Fas cDNAs were transiently overex- 
pressed under the control of the cytomegalovirus promoter 
and enhancer in murine BW5147 cells (White et al., 1989). 
Fas surface expression and the proportion of cells lost 
in response to exposure to anti-Fas antibody were then 
assessed by flow cytometry. This system measures only 
apoptosis signals delivered by CH11 antibody to the Fas 
protein encoded by the transfected allele because 
BW5147 cells do not express Fas or FasL under these 
conditions (L. Chert and M. J. L,  unpublished data) and 
because CH11 does not recognize murine Fas (Itoh et al., 
1991). Results from transfections of plasmids containing 
full-length mutant cDNAs from patients 2-5 and a normal 
cDNA (normal Fas allele of patient 5) were compared with 
those of control pCI plasmid with no insert (Figure 4). Each 
transfected Fas allele, with the exception of that from pa- 
tient 4, was expressed on the surface of 40%-50% of the 
BW5147 cells (open and hatched bars in Figure 4). The 
deletion in the extracellular portion of the Fas protein en- 
coding the mutant allele of patient 2 prevented detection 
with MAb UB2, CH11, or ZB4; but surface expression of 
this mutant protein could be detected on 39% of the 
transfected cells with a rabbit polyclonal antibody recog- 
nizing the 15 amino-terminal residues of Fas (hatched bar 
in Figure 4). The mutant allele of patient 4, truncated at 
the intracellular side of the membrane-spanning domain, 
might be predicted to have low cell surface expression 
because of the loss of charged intracellular anchoring resi- 
dues. Indeed, expression of the mutant protein could be 
detected on only 8%-12% of the transfected cells using 
several anti-Fas antibodies, including CH11, UB2, ZB4, 
and the polyclonal rabbit anti-peptide described above. 
Fas Detects in Human Autoimmune Lymphoproliferative Disorder 
941 
[ ]  70- 
O~ 60- 
"~ • ~0- T 
xo  i i  
W _.j 40" 
m ~ 
t,L. 0 3O- 
~' • 20- 0 0 
NI Fasplasmid, gg 0 I 10 
Mut Fas plasmid, ~g 0 0 
pCI (no insert), Ixg 10 10 
1o1101101 1o11o110 1ollo1 o 1o 1o 1o 
10 ~at.3en! 20.1 I 10 !at:nl 30"1 10 !at:n! 40"1 10 ~a:nl 50"1 
o1,19.9 o1,19.9 o1,1o9 o1,19  
Figure 5. Mutant Fas Alleles Have a Dominant 
Interfering Effect on Apoptosis Mediated by a 
Normal Fas Allele 
Cotransfections ofBW5147 murine thymoma 
cells with pCI-based expression plasmids con- 
taining no insert, the normal Fas allele (NI Fas 
plasmid), or mutant Fas alleles (Mut Fas plas- 
mid) as indicated. Titrations of 10, 3, and 0.1 
~g mutant Fas-containing plasmids with 10 p.g 
of normal Fas-containing plasmids were tested 
as shown. Total DNA in the transfection was 
kept constant (20 p.g) by the inclusion of the 
backbone pCI plasmid with no insert where 
neceassary. Y axis shows percent of BW5147 
cells that express human Fas, as detected by 
MAb UB2 (open bars) and percent cell loss 
after exposure to MAb CH11 (closed bars). Cell 
loss values are the arithmetic means with stan- 
dard deviations from three independent deter- 
minations. 
The transfected pools of cells were then exposed to 
CH11, and the fractional cell loss due to Fas-mediated 
apoptosis was measured. Only the normal Fas allele con- 
ferred upon the BW5147 cells the ability to respond signifi- 
cantly to a CH11 apoptotic stimulus (closed bars in Figure 
4). As illustrated by the equivalent height of the open and 
closed bars for the normal allele of patient 5 in Figure 
4, expression of this normal Fas cDNA construct caused 
essentially all transfected cells expressing Fas to be killed 
within 9 hr after exposu re to anti-Fas antibody. By contrast, 
cell loss in transfectants with mutant Fas was not different 
from cell loss in the transfectant with the control pCI plas- 
mid. No transfection of the mutant allele of patient 1 was 
attempted because its early truncation in CRD1 would pre- 
clude surface expression of any Fas protein. We con- 
cluded that ALPS-associated mutations could abrogate 
Fas-mediated apoptosis signals by different mechanisms: 
the mutant Fas of patient 2 failed to interact extracellularly 
with CH11 antibody, that of patient 4 (and presumably 
patient 1) could not achieve substantial surface expres- 
sion, and those of patients 3 and 5 failed to transmit death 
signals. 
Dominant Interference with Signaling for Cell Death 
To explain why the mutant Fas genes caused defective 
T cell apoptosis in heterozygous form, we investigated 
whether mutant Fas proteins could interfere with apoptotic 
signaling when coexpressed with normal Fas. Dominant 
negative interactions have been shown previously to im- 
pair apoptosis in the TNF/'rNFR pathway (Tartaglia and 
Goeddel, 1992). Using a similar approach, we transfected 
10, 3, or 0.1 I~g of the expression constructs containing 
the mutant alleles for patients 2-5 together with 10 I~g of 
plasmid containing the normal Fas allele (Figure 5). The 
total DNA in each transfection was adjusted to 20 I~g by 
including compensating amounts of the control pCI plas- 
mid. Transfection of equal amounts of plasmid containing 
normal and mutant Fas alleles resulted in Fas surface 
expression on 43%-55% of the BW5147 cells, equal to 
transfectants with normal Fas alone (open bars in Figure 
5). However, cotransfection of any of the mutant alleles 
with the normal allele abrogated cell loss after Fas cross- 
linking (closed bars in Figure 5). The dominant interfering 
effect diminished in a dose-dependent fashion as the ratio 
of plasmid expressing the mutant allele was decreased. 
The reduction in cell loss we observed was approximately 
equal to that expected based on the probability of ran- 
dom assembly of trimeric complexes with no mutant 
subunit (for 10 I~g each of normal and mutant Fas, P = 
(1/2)3 = 0.125). 
The mutant Fas alleles from patients 3 and 5 were also 
assessed for their ability to inhibit apoptosis mediated by 
endogenous Fas expressed in human Jurkat cells (Figure 
6). To measure Fas expression from the transfected plas- 
mid, we adjusted the fluorescence gate to detect only cells 
expressing Fas above the levels found on untransfected 
Jurkat cells. Significant overexpression, as measured by 
anti-Fas antibody staining, was achieved after transfection 
of 20 I~g of normal or mutant plasmids (open bars in Figure 
6). Nonetheless, as observed in the mouse cell system 
described above, mutant Fas from patients 3 and 5 sub- 
stantially diminished Fas-mediated cell loss in response 
to CH11 binding. 
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Figure 6. Mutant Fas Alleles from Two ALPS Patients Suppress 
Apoptosis in Human Jurkat Cells 
Transfections of pCI-based plasmids containing no insert, mutant, or 
normal alleles. Y axis shows percent of Jurkat cells expressing Fas 
above the level of untransfected cells (open bars) and percent cell 
loss after exposure to MAb CH11 (closed bars). 
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Discussion 
Our study associates a molecular defect in T lymphocyte 
apoptosis with a human disorder that we have termed 
ALPS. This syndrome is characterized by severe multisys- 
tern autoimmune disease and extreme overpopulation of 
lymph nodes, particularly with a normally rare subset of 
TCR-CD3+CD4-CD8 - lymphocytes. Because these find- 
ings are reminiscent of those manifested by Fas-deficient 
MRLIIpr mice, we studied the structure of Fas as a candi- 
date disease gene. Each child with ALPS had a unique 
Fas gene mutation, and these mutations had differing ef- 
fects on Fas. Patient 1 had an early single base deletion 
and frameshift, precluding the production of a Fas protein 
capable of surface expression. This mutation resembled 
typical recessive loss-of-function mutations. All of the re- 
maining four patients had mutations that could be pre- 
dicted to produce abnormal Fas protein: two splice muta- 
tions leading to deletions either within the extracellular 
domain (patient 2) or spanning the intracytoplasmic an- 
choring region and death domain (patient 4); a point muta- 
tion causing the nonconservative substitution of proline 
for threonine in the death domain (patient 3); and a death 
domain point mutation producing a premature termination 
(patient 5). All children had a defect in apoptosis of pheno- 
typically normal, mature T cells after either TCR restimula- 
tion or exposure to anti-Fas antibody. The spectrum of 
mutations we describe suggests that the Fas protein, spe- 
cifically with intact extracellular CRDs (Banner et al., 1993; 
Nagata and Golstein, 1995) and a functional intracytoplas- 
mic death domain (Tartaglia et al., 1993), is necessary for 
normal apoptotic signaling in mature human T lympho- 
cytes. 
Despite the clear causative relationship between Fas 
defects and lymphoproliferation with autoimmunity in the 
mouse, it was possible that the human Fas mutations we 
found were common in the population and coincidental to 
the clinical findings of ALPS in the patients we studied. 
Three lines of evidence argued against this hypothesis. 
First, the Fas genes from 100 unrelated copies of chromo- 
some 10 in 50 individuals did not contain any of these 
mutations. In addition, 30 normal subjects screened for 
functional defects in Fas-specific lymphocyte apoptosis 
induced by anti-Fas MAb did not manifest the killing de- 
fects seen in lymphocytes with heterozygous Fas muta- 
tions. Finally, direct analysis of four of the mutant alleles 
by cell transfection showed that they were unable to trans- 
mit a death signal and had dominant interfering effects 
on killing mediated by nonmutant Fas. Taken together, 
these results indicate that the mutations we have identified 
are not normal polymorphisms and are closely associated 
with abnormal lymphocyte apoptosis and the ALPS dis- 
ease state. 
The mutations we have found indicate that programmed 
mature T cell death via the Fas molecule is a potentially 
critical extrathymic mechanism for maintaining self-toler- 
ance in human (for reviews see Schwartz, 1989; Critchfield 
et al., 1995). Tolerance established in the periphery could 
prevent autoimmunity to antigens expressed only in spe- 
cific tissues or only after the perinatal period. Such anti- 
gens may not be presented in the thymus prior to popula- 
tion of the secondary lymphoid organs. Furthermore, 
self-tolerance may be intimately linked to peripheral T cell 
homeostasis. Thus, the physiologic T cell response to a 
peptide antigen may comprise a dramatic increase in the 
numbers of specifically responding T cells followed by a 
nearly equal reduction over time (McHeyzer-Williams and 
Davis, 1995). Elimination of T cells after activation by anti- 
gen maintains a diverse repertoire and prevents accumu- 
lation of potentially harmful cells that could cross-react 
with self-antigens. Thus, interference with T cell death in 
the periphery could disrupt normal homeostasis and pre- 
dispose one to autoimmune phenomena. 
In our patients, the Fas defects were associated with 
impaired apoptosis after TCR ligation of single-positive 
(CD4 ÷ or CD8 ÷) activated, mature T lymphocytes. Never- 
theless, the cells that accumulated in the circulation and 
secondary lymphoid tissue were TCR-CD3 ÷ double-nega- 
tive T lymphocytes, the cell type that is also expanded in 
Iprand gld mice. In the mouse, the excess double-negative 
T cells are derived from chronically activated single- 
positive T cells, principally CD8 ÷ T cells, that have failed 
to die (Giese and Davidson, 1995). In Ipr mice as well as 
in four of our ALPS patients, the double-negative cells 
display TCR~,  but patient 4 also had increased circulat- 
ing TCR76 double negatives. Thus, at least in humans, 
Fas-induced apoptosis may govern the homeostasis of 
circulating ~,8 ÷ T cells. The family history of Hodgkin's dis- 
ease in the father and uncle of patient 3 further suggests 
that abnormal lymphocyte survival may allow cells failing 
to be killed to accumulate mutations that lead to mali- 
gancy, as noted for Bcl-2 defects (Thompson, 1995). 
As in MRL/Ipr mice, disease in ALPS patients is primarily 
mediated by humeral rather than cell-mediated immunity. 
In both species, hypergammaglobulinemia is prominent. 
In MRLIIpr mice, autoantibodies, especially antinuclear 
antibodies, form immune complexes that are deposited in 
the kidney to cause glomerulonephritis. Autoantibodies 
were seen only in ALPS patients 3 and 5, and antinuclear 
antibodies were not observed. However, patient 2 did de- 
velop glomerulonephritis, and all children with ALPS had 
autoimmune cytopenias and rashes. These abnormalities 
of humoral immunity may be due in part to dysregulation 
of helper T cells (Giese and Davidson, 1995), but also may 
stem from the increase in absolute B cell numbers in ALPS 
patients. Indeed, Fas defects may impair the homeostasis 
of multiple immune cell types to produce a complex immu- 
noregulatory disorder. 
One of the most intriguing questions regarding ALPS is 
why the children with heterozygous mutations were af- 
fected while their parents were not. Several explanations 
were considered. The occurrence of novel Fas mutations 
in the affected children was ruled out by demonstrating 
that each was inherited from a carrier parent. Interestingly, 
however, parental genetic mosaicism was observed in 
mother 4, who had both a normal and a mutant Fas allele 
with the same allotype and whose apoptosis defect was 
less marked than that of her affected son. Also excluded 
in our families was the model of simple recessive inheri- 
tance, because in all five ALPS patients, one Fas allele 
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was mutated while the other was normal. Our findings are 
thus in contrast with the mouse Ipr mutation as well as to 
recessive mutations of each Fas allele recently described 
in two human siblings with autoimmunity and lymphoproli- 
feration (Rieux-Laucat et al., 1994, Twelfth European Im- 
munology Meeting, meeting abstract). Except for the mu- 
tation of patient 1, most consistent with a loss of function, 
the Fas-associated mutations in our ALPS patients are 
best modeled as dominant mutations producing a cellular 
resistance to apoptosis and also contributing to a clinical 
disease phenotype. This model is supported by demon- 
stration that patients and, in families 2 and 4, maternal 
carriers expressed mutant mRNA and manifested efects 
in the Fas-specific lymphocyte apoptosis pathway. The 
ability of mutant Fas alleles from patients 2-5 to prevent 
cell death via normal Fas is further evidence for a dominant 
cellular phenotype. 
Our failure to find Fas defects in a control population 
suggests that Fas mutations, whether of a loss-of-function 
or dominant interfering type, are highly correlated with 
ALPS. However, the fact that parents with the same muta- 
tions (and even with demonstrable apoptosis defects in 
vitro) do not have overt clinical symptoms indicates that 
Fas abnormalities cannot be the sole determinant of 
ALPS. Concomitant environmental or genetic factors, 
such as mutations in other immunoregulatory genes, are 
required to produce ALPS. Although extensive research 
in the mouse has clearly established a causative role for 
Fas mutations in inducing cellular defects and autoim- 
mune disease, this research has also proven that host 
strain differences, due to as yet undefined modifier genes, 
make a major contribution to disease phenotype (Theophi- 
Iopoulos and Dixon, 1968). The typical Ipr autoimmune 
syndrome of glomerulonephritis, vasculitis, and arthritis 
is regularly manifested at an early age in the MRL mouse 
background. By contrast, the same Ipr mutation causes 
essentially no autoimmune disease when bred onto the 
C57BL/6 background. On other backgrounds, such as 
C3H, the onset is delayed and the autoimmune manifesta- 
tions are milder than in MRL mice. Thus, it is not su rprising 
that in an outbred human population, individuals bearing 
the same Fas gene mutation may have dramatically differ- 
ent phenotypes. Defining the additional segregating 
gene(s) that causes expression of the full manifestations 
of ALPS in the presence of Fas dysfunction will be im- 
portant for understanding how Fas participates in immune 
regulation. Examples of such loci altering expressivity in 
mouse phenotypes include the recently defined modifier 
of the murine gene defect in multiple intestinal neoplasia 
(Dietrich et al., 1993), as well as the combinatorial utoim- 
mune effects of heterozygous gld and Ipr ~g mutations (Ki- 
mura and Matsuzawa, 1994). Human genetic loci known 
to affect expression of disease phenotypes are just begin- 
ning to be identified. To date these include the polymor- 
phic minisatellite at the human insulin gene locus, now 
shown to be a transcription regulator that when expanded 
predisposes to development of diabetes (Davies et al., 
1994; Kennedy et al., 1995), and the digenic form of retini- 
tis pigmentosa, a progressive blindness due to heterozy- 
gous mutations at two loci, peripherin/RDS and ROM1, 
that encode proteins colocalizing within the retinal photo- 
receptor (Kajiwara et al., 1994). 
In ALPS patients, defects that might convert an aysmp- 
tomatic Fas abnormality to overt disease are likely to be 
inherited from the parent who does not carry a Fas muta- 
tion. Recent elucidation of molecules involved in pro- 
grammed death pathways suggests an abundance of 
potential candidate genes, including FasL, Bcl-2, IL-I~-con- 
verting enzyme proteases (Thompson, 1995; Enari et al., 
1995; Los et al., 1995), and genes that regulate the expres- 
sion of these molecules. The TNF/TNFR pathway also 
plays an important role in T lymphocyte apoptosis 
(M. J. L., unpublished data) and could be impaired in pa- 
tients with ALPS. Alternatively, the unaffected carrier par- 
ents may have genes that protect against disease caused 
by abnormal T cell apoptosis. Further study of kindreds 
of ALPS patients with heterozygous Fas mutations may 
implicate one or even several modifier loci. 
The discovery of five unique human Fas mutations in 
patients with lymphoproliferation and autoimmunity has 
provided evidence that mature lymphocyte apoptosis is 
important in maintaining human self-tolerance. Four of 
these mutants encode abnormally expressed Fas proteins 
that cause dominantly inherited apoptosis defects. These 
mutations constitute valuable tools for defining how Fas 
chains interact with each other within a receptor complex, 
with extracellular ligand, and with intracellular mediators 
of downstream signaling. Moreover, these mutations have 
provided a framework for understanding the molecular ba- 
sis of a recently described human disorder, ALPS. What 
the human mutations reveal, which is not evident from 
the studies in the Ipr mouse model, is that heterozygous 
dominant interfering versions of Fas exist and that these 
can impair apoptosis and predispose to a severe disease 
in humans. 
Experimental Procedures 
Subject Enrollment and Cell Culture and Stimulation 
Participating families consented to evaluation and follow-up at the 
Warren Magnuson Clinical Center at the National institutes of Health 
under an approved clinical study protocol. Extensive medical assess- 
ments and complete family histories were obtained. Blood donated 
by unrelated healthy controls was processed in parallel to patient sam- 
ples in all assays. PBLs were isolated over FicolI-Hypaque gradients 
(Pharmacia Biotech, Piscataway, NJ) and in some instances were cryo- 
preserved for up to 4 years prior to the present study without substantial 
loss of viability. PBLs at 106/ml were activated with 10 ~tg/ml PHA on 
day 0 of culture in RPMI 1640 with 10% fetal calf serum, 2 mM gluta- 
mine, and peniciUin-streptomicin; o  day 3 the TCR stimulator anti- 
CD3 (OKT3; Ortho Diagnostic Systems, Raritan, N J) was added, and 
cultures were then maintained inrecombinant human 11_-2 (60 IU/ml) 
(Midwest Medical, Bridgeton, MO) with refeeding every 48-72 hr there- 
after for up to 2 weeks before analysis. Some cells were cryopreserved 
after the initial stimulation and thawed in IL-2 at least 48 hr prior to 
analysis. 
Detection of Patient Mutations 
DNA and RNA samples were prepared from activated lymphocytes 
using standard methods (Sambrook et al., 1989). For cDNA analysis, 
RT-PCR was performed using a cDNA cycle kit (Invitrogen, San Diego, 
CA) and Fas-specific primers. Products were visualized in ethidium 
bromide-stained agarose gels and cloned in the TA plasmid pCRII 
(Invitrogen), propagated inEscherichia coil DH5~, and sequenced by 
the dideoxy method with 32p end-labeled Fas primers and a PCR cyclist 
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kit (Stratagene, La Jolla, CA). PCR of genomic DNA with primers flank- 
ing each exon provided templates for direct sequencing. Cloned geno- 
mic PCR products were also sequenced. Primers were selected with 
the assistance of PRIMER (Whitehead Institute, Cambridge, MA) and 
DNA* programs (DNA*, Madison, Wl) and the GenBank genomic se- 
q uence entries X81335-X81342 (Behrman net al., 1994); primers used 
are listed in Table 2. PCR was carried out in 1 x GeneAmp PCR buffer 
(Perkin-Elmer, Norwalk, CT) with each primer at 0.25 pM, each dNTP 
at 0.2 mM, and 1.25 U of Amplitaq DNA polymerase (Perkin-Elmer) 
in a total volume of 50 t~1. A 5 rain interval at 94°C was followed by 
30 cycles of 94°C for 30 s, 59°C for 60 s, and 72°C for 60 s in a 9600 
Thermal Cycler (Perkin-Elmer). 
Documentation that both alleles had been fully examined included 
complete sequence determination of normal and mutant clones as 
well as demonstration of previously described allotypes consisting of 
silent nucleotide substitutions at 416 and 836 (Fiucci and Ruberti, 
1994) in families 4 and 5. For parents with homozygous allotypes, four 
to ten cDNA clones were sequenced. 
Single strand conformation polymorphism was assayed as de- 
scribed elsewhere (Hyashi, 1992; Puck et al., 1995). Genomic DNA 
segments of 83-480 bp were amplified with primers (Table 2) sur- 
rounding the site of mutation for each patient as follows: patients 1 
and 2, ex3-5' and ex3-3'; patient 3, ex9-5' and 989-962; patient 4, 
ex7-5' and 792-767; and patient 5, ex9-5' and 1243-1221R. Primers 
were end labeled with 32p for autoradiographic detection of boiled 
single-stranded products on Hyrdolink MDE acrylamide gels (AT Bio- 
chem, Malvern, PA) with or without 10O/o glycerol. The 465 bp segment 
surrounding mutation of patient 5 was trimmed to 301 bp by digestion 
with Taql to facilitate mutation detection. Templates included genomic 
DNA samples from 20 unrelated CEPH pedigree members (Coriell Cell 
Repositories, Camden, N J) and from 30 additional unrelated normal 
subjects as well as genomic and cloned DNA from the five ALPS pa- 
tients. 
Flow Cytometry Analysis 
Analysis of Fas surface expression was carried out by incubating 10 ~ 
to 106 cells at 4°C for 30 min with anti-human Fas MAb UB2 or ZB4 
(Kamiya Biochemical Corporation, Thousand Oaks, CA), washing, and 
then staining with FITC-conjugated anti-mouse immunoglobulin G1 
(IgG1) (Pharmingen, San Diego, CA). When CH11 was used for stain- 
ing, FITC-conjugated goat anti-mouse IgM (Pharmingen) was the sec- 
ond reagent. To stain the mutant Fas allele of patient 2, a rabbit poly- 
clonal IgG anti-hu man Fas (peptide 21-38) (Santa Cruz Biotech, Santa 
Cruz, CA) was used as a primary reagent, and FITC-conjugated goat 
anti-rabbit IgG was used for detection. Flow cytometric quantitation 
of T cell death was performed by resuspending washed cells from two 
wells in 400 Ill of FACS buffer (1 x PBS with 1% BSA and 0.01O/o 
sodium azide) plus 30 ng/rnl propidium iodide. Total cells were col- 
lected for 1 min without live gating, and the viable cells were quanti- 
tated by gating on propidium iodide exclusion and forward light scatter 
as previously described (Boehme and Lenardo, 1993). Activated cell 
cultures were also stained for T cell surface markers CD3, CD4, CD8, 
TNFR p55 and p75, and CD25 by standard methods (Z~iga-PflL~cker 
et al., 1993). Flow cytometry was carried out on a FACScan flow 
cytometer (Becton-Dickinson, Mountain View, CA) using CellQuest 
software. 
Induction of Apoptosis 
Apoptosis was induced by incubating cells without or with an apoptotic 
stimulus followed by marking of nonviable cells with propidium iodide 
and quantitation by flow cytometry. Activated PBLs were grown in IL-2 
for 48 hr prior to in vitro CD3 exposu re. Flat bottom microwells (Falcon, 
Franklin Lakes, N J) were untreated or coated with anti-human CD3~ 
MAb (84.1) at a concentration of 1 i~g/ml (Wacholtz and Lipsky, 1993). 
Plates were washed three times with PBS, and 50,000 cells were 
added per well in 200 Ill. The cells were incubated at 37°C and 5% 
CO2 for 24 hr, and viable cells were assayed as above. The per- 
cent cell loss was calculated as follows: [(1 - cell number recovered 
from wells with MAb)/(cell number recovered from wells without 
MAb)] x 100. 
Apoptosis restricted to the Fas pathway was detected by exposure 
of test cells to an agonist anti-Fas MAb (CH11 ; Kamiya Biomedical), 
while control cells received no antibody. At the time of apoptosis assay, 
an aliquot of cell population was tested for proliferation by [3H]thymi- 
dine incorporation. Assay of CH11-mediated eletion was carried out 
using stimulated mature T cells maintained in I L-2; 50,000 cells per well 
were cultured in flat-bottomed microwells with 25 ng/ml actinomycin D 
(Sigma, St. Louis, MO). CH11 was then added to the experimental 
wells for 24 hr. Viable cells were quantitated by flow cytometry and 
percent cell loss was calculated. 
Apoptosis in Transfected Cells Expressing Normal 
and Mutant Human Fas 
BW5147 murine thymoma ceils (White et al., 1989) and human-derived 
Jurkat cells were grown in RPMI 1640 with 10% fetal calf serum, 2 
mM glutamine, penicillin-streptomycin, and 50 mM 13-mercapto- 
ethanol (Biofluids, Rockville, MD). Full-length cDNA clones from the 
mutant alleles of patients 2-5 were released from pCRII with EcoRI 
and recloned into EcoRI-digested mamallian CMV expression vector, 
pCI (Promega, Madison, WI). These plasmid constructs (10-25 p.g) 
with the correct orientation or pCI without a Fas insert were electropor- 
ated into 4 x 106 BW5147 cells/ml cells in 0.4 ml in an Electrocell 
manipulator 600 (BTX Corporation, San Diego, CA). After pulse dis- 
charge at settings 260 V, 1050 p~F, and 720 ~, the cells were immedi- 
ately placed in 8 ml of medium and incubated for 12 hr. Viable cells 
were isolated over Lympholyte M (Cedar Lane, Hornby, Ontario, Can- 
ada). For induction of apoptosis, 50,000 cells in 200 ~1 were treated 
with 0.5 i~g/ml CH11 in triplicate wells for 9 hr for BW5147 cells or 
with 10 or 100 ng/ml CH11 in triplicate wells for 4 hr for Jurkat ceils; 
parallel control cultures received no antibody treatment. Viable cells 
excluding propidium iodide were enumerated by flow cytometry, and 
expression of Fas was determined as 
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